Psyence Biomedical Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	1.01	-51.16	-3.21	-1.86
Depreciation & Amortization	0	0	-	-
Stock-Based Compensation	-	0.32	0.22	0.33
Other Operating Activities	-4.36	49.07	-0.08	-
Change in Accounts Receivable	-0.1	0.11	-0.11	0.1
Change in Accounts Payable	-0.36	-1.04	1.66	0.03
Change in Other Net Operating Assets	0.07	-0.25	-0.07	0
Operating Cash Flow	-3.73	-2.95	-1.59	-1.4
Capital Expenditures	-0.01	-0.01	-	-
Other Investing Activities	-0.01	-	-	-0.03
Investing Cash Flow	-0.02	-0.01	-	-0.03
Short-Term Debt Issued	1	2.5	-	-
Total Debt Issued	1	2.5	-	-
Short-Term Debt Repaid	-	-0.15	-	-
Total Debt Repaid	-	-0.15	-	-
Net Debt Issued (Repaid)	1	2.35	-	-
Issuance of Common Stock	1.74	-	-	-
Other Financing Activities	6.41	-	1.17	-1.63
Financing Cash Flow	9.15	2.35	1.17	-1.63
Net Cash Flow	5.4	-0.6	-0.42	-3.06
Free Cash Flow	-3.74	-2.95	-1.59	-1.4
Free Cash Flow Per Share	-154.58	-270.67	-	-
Levered Free Cash Flow	-3.39	-1.71	-0.32	-
Unlevered Free Cash Flow	-3.39	-1.68	-0.32	-

Updated Jan 23, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q